Stock Events

Stock Events

Mersana Therapeutics 

$29.08
50
+$0.04+0.14% Monday 21:00

Statistics

Day High
30.36
Day Low
28.78
52W High
30.39
52W Low
5.21
Volume
704,861
Avg. Volume
141,820
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

4MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-4.87
-3.28
-1.68
-0.09
Expected EPS
-3.054286
Actual EPS
N/A

Financials

-170.86%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
40.5MRevenue
-69.19MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MRSN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap445.17M
ADC Therapeutics develops ADCs targeting hematological malignancies and solid tumors, overlapping with Mersana's focus.
Macrogenics
MGNX
Mkt Cap187.5M
MacroGenics provides innovative antibody-based therapies for cancer, competing in the same biopharmaceutical space as Mersana.
Allogene Therapeutics
ALLO
Mkt Cap786.66M
Allogene Therapeutics works on allogeneic CAR T cell therapies, a different but competing approach in cancer treatment.
Gilead Sciences
GILD
Mkt Cap163.06B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space with CAR T and other cancer therapies.
Novartis
NVS
Mkt Cap278.64B
Novartis offers a broad range of oncology treatments, including CAR T-cell therapies, competing across multiple areas with Mersana.
Pfizer
PFE
Mkt Cap146.36B
Pfizer has a diverse oncology portfolio, including ADCs, that competes with Mersana's therapeutic approaches.

About

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Martin H. Huber M.D.
Employees
102
Country
United States
ISIN
US59045L1061

Listings

0 Comments

Share your thoughts

FAQ

What is Mersana Therapeutics stock price today?▼
The current price of MRSN is $29.08 USD — it has increased by +0.14% in the past 24 hours. Watch Mersana Therapeutics stock price performance more closely on the chart.
What is Mersana Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mersana Therapeutics stocks are traded under the ticker MRSN.
Is Mersana Therapeutics stock price growing?▼
MRSN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Mersana Therapeutics has showed a +242.02% increase.
What is Mersana Therapeutics revenue for the last year?▼
Mersana Therapeutics revenue for the last year amounts to 40.5M USD.
What is Mersana Therapeutics net income for the last year?▼
MRSN net income for the last year is -69.19M USD.
How many employees does Mersana Therapeutics have?▼
As of May 17, 2026, the company has 102 employees.
In which sector is Mersana Therapeutics located?▼
Mersana Therapeutics operates in the Health & Wellness sector.
When did Mersana Therapeutics complete a stock split?▼
The last stock split for Mersana Therapeutics was on July 28, 2025 with a ratio of 1:25.
Where is Mersana Therapeutics headquartered?▼
Mersana Therapeutics is headquartered in Cambridge, United States.